HeartSciences (NASDAQ:HSCS) Issues Earnings Results, Beats Expectations By $0.05 EPS

HeartSciences (NASDAQ:HSCS) issued its earnings results on Monday. The company reported ($0.85) EPS for the quarter, topping the consensus estimate of ($0.90) by $0.05, Zacks reports.

HeartSciences Trading Down 3.1%

Shares of NASDAQ:HSCS traded down $0.08 during trading on Monday, reaching $2.47. The company had a trading volume of 288,996 shares, compared to its average volume of 55,663. The company has a fifty day moving average of $3.01 and a two-hundred day moving average of $3.43. The stock has a market capitalization of $6.55 million, a P/E ratio of -0.30 and a beta of 2.57. HeartSciences has a 12 month low of $2.01 and a 12 month high of $6.47.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in HeartSciences stock. Geode Capital Management LLC purchased a new stake in shares of HeartSciences Inc. (NASDAQ:HSCS) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 11,599 shares of the company’s stock, valued at approximately $43,000. Geode Capital Management LLC owned approximately 0.51% of HeartSciences as of its most recent SEC filing. 17.24% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

HSCS has been the topic of a number of recent analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of HeartSciences in a report on Monday, December 8th. Wall Street Zen upgraded shares of HeartSciences from a “sell” rating to a “hold” rating in a research report on Friday, October 3rd. Finally, Ascendiant Capital Markets lowered their price objective on HeartSciences from $15.00 to $9.00 and set a “buy” rating on the stock in a research report on Wednesday, October 1st. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $10.50.

HeartSciences Company Profile

Heart Test Laboratories, Inc, a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals.